JG
CORT icon

Jefferies Group’s Corcept Therapeutics CORT Stock Holding History

Jefferies Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-59,800
Closed -$1.18M – 1682
2021
Q3 		$1.18M Buy
59,800
+11,500
+24% +$241K 0.01% 931
2021
Q2 		$1.06M Buy
+48,300
New +$1.07M 0.01% 974
2020
Q4 		– Sell
-19,000
Closed -$331K – 1583
2020
Q3 		$331K Buy
19,000
+3,400
+22% +$54.2K ﹤0.01% 1078
2020
Q2 		$262K Buy
+15,600
New +$219K ﹤0.01% 1036
2017
Q3 		– Sell
-150,000
Closed -$1.77M – 2375
2017
Q2 		$1.77M Buy
+150,000
New +$1.63M 0.01% 993

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jefferies Group's CORT Position: Q4 2021 in Review

Jefferies Group sold out of Corcept Therapeutics (CORT) in Q4 2021, closing a stake of 59,800 shares — an estimated $1.18M sold.

Jefferies Group first reported a position in CORT in Q2 2017 and held it in 5 quarters. The position peaked at $1.77M in Q2 2017. 208 funds tracked by Wall St. Rank hold CORT as of Q4 2021.

  • Jefferies Group reported no remaining Corcept Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jefferies Group sold 59,800 Corcept Therapeutics shares in Q4 2021, an estimated $1.18M.
  • Jefferies Group first reported a position in Corcept Therapeutics in Q2 2017 and held it in 5 quarters.
  • Jefferies Group's Corcept Therapeutics position peaked at $1.77M in Q2 2017.
  • 208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.